Profile: Aptose Biosciences Inc (APTO.OQ)
23 Aug 2019
Aptose Biosciences Inc. (Aptose), incorporated on November 1, 2006, is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. The Company's product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products.
The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein, and can inhibit expression of the c-Myc oncogene, leading to cell cycle arrest and programmed cell death (apoptosis) in human-derived solid tumor and hematologic cancer cells. In nonclinical pharmacology studies, APTO-253 demonstrates in vivo anti-tumor activity against xenograft models of solid tumors and hematologic cancers, with acute myeloid leukemia (AML) cells exhibiting a particular sensitivity to APTO-253. APTO-253 has demonstrated potent and selective in vitro antiproliferative activity against a variety of leukemia cell lines, including AML, ALL and chronic myeloid leukemia (CML), as well as non-Hodgkin's lymphoma (NHL) cell lines, with IC50 values ranging from 0.007 to 0.3 micrometer (uM).
The Company's Small molecule program is focused on investigating series of Aptose compounds for veterinary medicine. The Company has agreement with Moffitt Cancer Center for global rights to multi-targeting, single-agent inhibitors for the treatment of hematologic and solid tumor cancers. The small molecule agents are highly differentiated inhibitors of the Bromodomain and Extra-Terminal motif (BET) protein family members, which target specific kinase enzymes. The molecules developed by Moffitt exhibit nanomolar potency against the BET family members and specific oncogenic kinases which, when inhibited, are synergistic with BET inhibition. Under the agreement, the Company has access to the drug candidates developed by Moffitt and the underlying intellectual property covering the chemical modifications enabling potent bromodomain (BRD) inhibition on the chemical backbone of a kinase inhibitor. The Company also has drug discovery partnership with Laxai Avanti Life Sciences (LALS) for the expertise in next generation epigenetic-based therapies. Under the agreement, LALS is responsible for developing multiple clinical candidates, including optimizing candidates derived from Aptose's relationship with the Moffitt Cancer Center.
Aptose Biosciences Inc
251 Consumers Rd Suite 1105
NORTH YORK ON M2J 4R3